The biosimilars space is expected to become increasingly competitive as reference brand companies try to retain market share in the face of their product’s dwindling patent life and biosimilar developers try to wrestle patient and market share from the reference brand product and other biosimilars. In this report, we discuss strategies—based on actual practices—that reference brand companies and biosimilar developers can use to flourish in the U.S. and EU5 pharmaceutical markets and emerging markets.